Paid Clinical Trials in Connecticut

Connecticut has 1,306 paid clinical trials enrolling now across cities including New Haven, Hartford and Stamford. Search by condition, age, or phase to find compensated research studies accepting participants near you.

Both patients and healthy volunteers may qualify. Most studies offer compensation for time and travel.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 28, 2026.

Filter results

State

City

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

1,161 clinical trials

↓ Download CSV

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

for Alzheimers Disease

Sites in New Haven +67 more locations

Sponsor: Hoffmann-La Roche

Sex: All·Age: 50 - 90

Code: NCT07177352·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

for Elevated Lp(a)

Drug: Muvalaplin

Sites in Stamford, Waterbury +128 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07157774·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

for Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Drug: Coramitug

Sites in New Haven +59 more locations

Sponsor: Novo Nordisk A/S

Sex: All·Age: 18+

Code: NCT07207811·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

for Cardiovascular Disease

Drug: Olpasiran

Sites in Waterbury, Greenwich +199 more locations

Sponsor: Amgen

Sex: All·Age: 50 - 105

Code: NCT07136012·Phase 3·Recruiting·Listed Aug 2025

Apply to this trial

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

for Diabetes Mellitus, Type 2

Drug: Empagliflozin

Sites in Stamford, Bridgeport +209 more locations

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT07064473·Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

for Colitis, Ulcerative

Sites in Hartford +50 more locations

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 12+

Code: NCT07196748·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

for Metastatic Colorectal Cancer (CRC)

Drug: Bevacizumab

Sites in New Haven, Hartford +81 more locations

Sponsor: Summit Therapeutics

Sex: All·Age: 18+

Code: NCT07228832·Phase 3·Recruiting·Listed Nov 2025

Apply to this trial

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

for Alzheimers Disease

Drug: Trontinemab

Sites in New Haven +32 more locations

Sponsor: Hoffmann-La Roche

Sex: All·Age: 50 - 90

Code: NCT07170150·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

for Hidradenitis Suppurativa (HS)

Drug: Povorcitinib

Sites in Farmington +25 more locations

Sponsor: Incyte Corporation

Sex: All·Age: 12 - 17

Code: NCT07213973·Phase 2·Recruiting·Listed Oct 2025

Apply to this trial

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

for Metastatic Castration-resistant Prostate Neoplasms

Drug: Pasritamig

Sites in Hartford +52 more locations

Sponsor: Janssen Research & Development, LLC

Sex: Male·Age: 18+

Code: NCT07164443·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

for Osteoarthritis

Drug: Orforglipron

Sites in Waterbury +25 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07153471·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

for Patients With Non-Small Cell Lung Cancer

Drug: OSE2101

Sites in Norwich +33 more locations

Sponsor: OSE Immunotherapeutics

Sex: All·Age: 18+

Code: NCT06472245·Phase 3·Recruiting·Listed Jun 2024

Apply to this trial

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

for Parkinson's Disease

Drug: Prasinezumab

Sites in New Haven +45 more locations

Sponsor: Hoffmann-La Roche

Sex: All·Age: 50 - 85

Code: NCT07174310·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

for Metabolic Dysfunction Associated Steatohepatitis (MASH)

Drug: Survodutide

Sites in New Haven, Bristol +161 more locations

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06632444·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

for Melanoma

Sites in New Haven +89 more locations

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06246916·Phase 3·Recruiting·Listed Feb 2024

Apply to this trial

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

for Triple Negative Breast Cancer

Sites in Stamford +123 more locations

Sponsor: Gilead Sciences

Sex: All·Age: 18+

Code: NCT05633654·Phase 3·Recruiting·Listed Dec 2022

Apply to this trial

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

for Breast Cancer

Sites in New Haven +168 more locations

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06492616·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

for Small-cell Lung Cancer

Drug: ZL-1310

Sites in New Haven +30 more locations

Sponsor: Zai Lab (Shanghai) Co., Ltd.

Sex: All·Age: 18+

Code: NCT07218146·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

for End Stage Kidney Disease

Drug: Clazakizumab

Sites in Middlebury, Bloomfield +145 more locations

Sponsor: CSL Behring

Sex: All·Age: 18+

Code: NCT05485961·Phase 2, Phase 3·Recruiting·Listed Aug 2022

Apply to this trial

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

for Metabolic Dysfunction Associated Steatohepatitis

Drug: Survodutide

Sites in Bristol +124 more locations

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06632457·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

for Pediatric Migraine

Sites in Stamford, Cromwell +82 more locations

Sponsor: Pfizer

Sex: All·Age: 6 - 17

Code: NCT04649242·Phase 3·Recruiting·Listed Dec 2020

Apply to this trial

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

for Carcinoma, Non-Small-Cell Lung

Drug: Amivantamab

Sites in New Haven +128 more locations

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06667076·Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

for Renal Cell Carcinoma (RCC)

Sites in New Haven +43 more locations

Sponsor: Exelixis

Sex: All·Age: 18+

Code: NCT05176483·Phase 1·Recruiting·Listed Jan 2022

Apply to this trial

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

for Breast Cancer

Sites in New Haven, Hartford +100 more locations

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07062965·Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

for Small-cell Lung Cancer

Drug: Durvalumab

Sites in New Haven, Norwich +48 more locations

Sponsor: Amgen

Sex: All·Age: 18 - 99

Code: NCT07005128·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

for Proteinuric Kidney Disease

Sites in New Haven, Middlebury +165 more locations

Sponsor: Vertex Pharmaceuticals Incorporated

Sex: All·Age: 10 - 65

Code: NCT05312879·Phase 2, Phase 3·Recruiting·Listed Apr 2022

Apply to this trial

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

for Triple-Negative Breast Cancer

Sites in New Haven +80 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06393374·Phase 3·Recruiting·Listed May 2024

Apply to this trial

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

Drug: LY3537982

Sites in Hartford +85 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06890598·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

for Colorectal Neoplasms

Drug: Amivantamab

Sites in Norwich +67 more locations

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06750094·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

for Heart Failure

Drug: Empagliflozin

Sites in Bridgeport +98 more locations

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06935370·Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

for Heart Failure With Preserved Ejection Fraction

Sites in Stamford +109 more locations

Sponsor: Amgen

Sex: All·Age: 18 - 99

Code: NCT07037459·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

Drug: LY3537982

Sites in New Haven +87 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06119581·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

for Obesity

Sites in Stamford +42 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18 - 75

Code: NCT06143956·Phase 2·Recruiting·Listed Nov 2023

Apply to this trial

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

for Acute Treatment of Migraine

Drug: Rimegepant

Sites in Stamford, Cromwell +62 more locations

Sponsor: Pfizer

Sex: All·Age: 6 - 17

Code: NCT04743141·Phase 3·Recruiting·Listed Feb 2021

Apply to this trial

A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

for Bipolar Disorder Type I With Mania

Drug: KarXT

Sites in New Haven +45 more locations

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18 - 65

Code: NCT06929273·Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

for Colorectal Neoplasms

Drug: Amivantamab

Sites in New Haven +78 more locations

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06662786·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

for Advanced Non-Small Cell Lung Cancer

Drug: Adagrasib

Sites in Norwich +191 more locations

Sponsor: Mirati Therapeutics Inc.

Sex: All·Age: 18+

Code: NCT04613596·Phase 2, Phase 3·Recruiting·Listed Nov 2020

Apply to this trial

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

for Crohn's Disease

Drug: Tulisokibart

Sites in New Haven +70 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 16 - 80

Code: NCT06430801·Phase 3·Recruiting·Listed May 2024

Apply to this trial

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

for Chronic Spontaneous Urticaria (CSU)

Drug: Remibrutinib

Sites in Farmington +127 more locations

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06868212·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

for Early Alzheimer's Disease

Sites in New Haven +35 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 50 - 85

Code: NCT07033494·Phase 2·Recruiting·Listed Jun 2025

Apply to this trial